Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Boston Scientific

Celsius Holdings

Clean Harbors

Copa Hlds

Dynatrace Inc

Wingstop

Several IBD 50 stocks are forming bullishly tight chart patterns. The post These Growth Stocks Seem Stalled.

These Growth Stocks Seem Stalled. That May Be A Good Thing.

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

ShockWave Medical (SWAV) Hits 52-Week High: Will it Continue?

Shockwave is creating a wave itself with takeover rumours and excellent Q1 fundamentals. The market has revised expectations for the company and now sees tremendous growth moving forward.

Shockwave Medical: Multiple Growth Levers To Drive Valuation Upside

Vita Coco

Intuitive Surgical

Novo Nordisk

Stryker

Because of their longevity, predictability, and stability, healthcare trends can persist for years. The companies covered today are fundamentally and technically robust stocks currently taking advantage of these trends.

3 Healthcare Trends to Ride for Longevity

SANTA CLARA, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Kevin Ballinger has joined its Board of Directors and will serve on Shockwave's Nominating and ESG Committee and the Compensation Committee of the Board.

Shockwave Appoints Kevin Ballinger to Board of Directors

Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.

Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets

Shockwave Medical Inc. NASDAQ: SWAV, the largest component within the iShares Russell 2000 ETF NYSEARCA: IWM, briefly cleared a cup-with-handle buy point on May 12, but reversed lower along with the broader market.

Shockwave Medical, Fast Grower, In Boston Scientific's Sights?

Shockwave C 2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries SANTA CLARA, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced the full commercial availability of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) Catheter to treat severely calcified coronary artery disease in select international markets.

Shockwave Medical Launches New Coronary IVL Catheter Internationally and Enrolls First Patient in All-Female Empower Study

Fiverr

Trade Desk

Fiverr's platform for hiring freelance workers is poised to benefit from the rising popularity of artificial intelligence applications. Demand for Shockwave Medical's devices is being driven by an aging demographic in the U.S. and other developed countries around the world.

3 Top Growth Stocks to Buy Now and Hold Forever

Shockwave Medical is Thursday's IBD Stock Of The Day as SWAV stock soars closer to a breakout on its big earnings beat and raise. The post Ballooning Sales, Profit Send Shockwave Into An Early Breakout appeared first on Investor's Business Daily.

Ballooning Sales, Profit Send Shockwave Into An Early Breakout

Shockwave Medical has upped its full-year 2023 guidance after its revenue beat across all of its product segments during its first quarter. The medical product company saw its revenue increase by 72% year-over-year to reach $161.1 million, ahead of consensus estimates of $147.3 million.

Shockwave Medical surges ahead: impressive 1Q performance leads to raised revenue guidance for 2023

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Shockwave Medical (SWAV) Q1 Earnings Top, Revenues Surge Y/Y

Shockwave Medical, Inc. (NASDAQ:SWAV ) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Debbie Kaster - Vice President, Investor Relations Doug Godshall - President and CEO Isaac Zacharias - President and CCO Trinh Phung - Vice President, Finance Conference Call Participants Adam Maeder - Piper Sandler Bill Plovanic - Canaccord Genuity Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Michael Polark - Wolfe Research Cecilia Furlong - Morgan Stanley Imron Zafar - Deutsche Bank Mike Matson - Needham Operator Good afternoon. And welcome to Shockwave's First Quarter 2023 Earnings Conference Call.

Shockwave Medical, Inc. (SWAV) Q1 2023 Earnings Call Transcript

Shockwave Medical (SWAV) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.39 per share a year ago.

Shockwave Medical (SWAV) Beats Q1 Earnings and Revenue Estimates

SANTA CLARA, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023.

Shockwave Medical Reports First Quarter 2023 Financial Results

SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the first quarter 2023 after market close on Monday, May 8, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Shockwave Medical Announces Details for Conference Call Discussing First Quarter 2023 Results and Participation in Upcoming Investor Conference

A well-known peer is apparently interested in acquiring the medical device maker. Shockwave produces and sells products that use sound to break up calcium in blood vessels.

Why Shockwave Medical Stock Blasted More Than 10% Higher on Friday

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Shockwave Medical Gets 10% Jolt, Leads Medical Gear Makers Higher

Shockwave Medical (SWAV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Shockwave Medical (SWAV) Moves 10.6% Higher: Will This Strength Last?

Shockwave just completed its purchase of Neovasc. Proposed new payment codes would benefit Shockwave's IVL system.

Why Shares of Shockwave Medical Jumped on Tuesday

A new Medicare rule could sweeten reimbursement for Shockwave Medical's systems, according to a report Tuesday that sent SWAV stock soaring. The post Why Shares Of Shockwave Medical, A Top 5% Stock, Just Skyrocketed appeared first on Investor's Business Daily.

Why Shares Of Shockwave Medical, A Top 5% Stock, Just Skyrocketed

Neovasc

SANTA CLARA, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”).

Shockwave Medical, Inc. Completes Acquisition of Neovasc

SANTA CLARA, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (“IVL”) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. (“Neovasc”).

Shockwave Medical Completes Acquisition of Neovasc

Investors need to pay close attention to Shockwave Medical (SWAV) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Shockwave Medical (SWAV) Stock?

Doximity

Transmedics Group Inc

Individual stocks don't deliver 10x returns very often, but it does happen. Doximity operates a social media platform exclusive to U.S. medical professionals, and pharmaceutical companies are clamoring for its available ad inventory.

News for Shockwave Medical Stock (SWAV)